Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Myra W. Popejoy"'
Publikováno v:
BMC Infectious Diseases, Vol 17, Iss 1, Pp 1-8 (2017)
Abstract Background Diabetes mellitus and hyperglycemia are associated with increased susceptibility to bacterial infections and poor treatment outcomes. This post hoc evaluation of the treatment of complicated intra-abdominal infections (cIAI) and c
Externí odkaz:
https://doaj.org/article/fa97e14e838e4cc8a1c0700dcd409c51
Autor:
Emmanuel Roilides, Negar Ashouri, John S. Bradley, Matthew G. Johnson, Julia Lonchar, Feng-Hsiu Su, Jennifer A. Huntington, Myra W. Popejoy, Mekki Bensaci, Carisa De Anda, Elizabeth G. Rhee, Christopher J. Bruno
Publikováno v:
Pediatric Infectious Disease Journal. 42:292-298
Autor:
Richard G. Wunderink, Daniel Gonzalez, Jason Y Kim, Satoshi Fujimi, Martin A. Croce, Natasha Broyde, Carisa De Anda, Joan R. Butterton, Myra W. Popejoy, Antoine Roquilly
Publikováno v:
Clinical Infectious Diseases. 73:e710-e718
Background Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) are associated with high mortality rates. We evaluated the efficacy and safety of tedizolid (administered as tedizolid phosphate) for treatme
Autor:
Dominik J Wolf, John S. Bradley, Myra W. Popejoy, Paula M. Bokesch, Ellie Hershberger, Valeri A Digtyar, Christopher M. Tan, Yoshihiko Murata, Anjana Grandhi, Mary Beth Dorr, Mekki Bensaci, Antonio Arrieta
Publikováno v:
Pediatric Infectious Disease Journal. 39:814-823
Background We prospectively evaluated efficacy and safety of daptomycin versus active comparator in children with acute hematogenous osteomyelitis (AHO). Methods Randomized, controlled, double-blind, global, multicenter, phase 3 trial. Patients 1-17
Autor:
Antoine Roquilly, Satoshi Fujimi, Daniel Gonzalez, Jason Y Kim, Martin A. Croce, Natasha Broyde, Joan R. Butterton, Myra W. Popejoy, Carisa De Anda, Richard G. Wunderink
Publikováno v:
Clinical Infectious Diseases. 73:1552-1553
Autor:
Myra W. Popejoy, Ellie Hershberger, Benjamin F. Miller, John C. Alverdy, Judith N. Steenbergen
Publikováno v:
Antimicrobial Agents and Chemotherapy. 60:4387-4390
Ceftolozane-tazobactam is active against Gram-negative pathogens, including multidrug-resistant Pseudomonas aeruginosa . In a subgroup analysis of patients with complicated intra-abdominal infections (cIAIs) involving P. aeruginosa from a phase 3 pro
Autor:
Carisa De Anda, Natasha Broyde, Jason Y Kim, Satoshi Fujimi, Antoine Roquilly, Richard G. Wunderink, Myra W. Popejoy, Martin Croce, Joan R. Butterton, Daniel Gonzalez
Publikováno v:
Open Forum Infectious Diseases
Background Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) are frequently caused by G+ cocci; TZD has potent in vitro activity against these pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). The VITA
Autor:
David L. Paterson, Jennifer A. Huntington, Ellie Hershberger, Daniel J Cloutier, Benjamin F. Miller, Myra W. Popejoy, Caleb A. Bliss, Obiamiwe Umeh, Keith S. Kaye, Judith N. Steenbergen
Publikováno v:
The Journal of antimicrobial chemotherapy. 72(1)
The increase in infections caused by drug-resistant ESBL-producing Enterobacteriaceae (ESBL-ENT) is a global concern. The characteristics and outcomes of patients infected with ESBL-ENT were examined in a pooled analysis of Phase 3 clinical trials of
Publikováno v:
Open Forum Infectious Diseases. 2
Publikováno v:
Infectious Diseases and Therapy
Introduction Ceftolozane/tazobactam is an antibacterial agent with potent in vitro activity against Gram-negative pathogens, including many extended-spectrum β-lactamase-producing Enterobacteriaceae and drug-resistant Pseudomonas aeruginosa. Because